Breaking News

U.S. May Home Prices Rise 0.4% From Previous Month: FHFA
Tweet TWEET

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences

    OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences

PR Newswire

BOTHELL, WA and VANCOUVER, Feb. 5, 2013

BOTHELL, WA and VANCOUVER, Feb. 5, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc.(NASDAQ: OGXI) announced today that Scott Cormack,
President and Chief Executive Officer, will provide a corporate presentation
at the following upcoming investor conferences:

  *BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 1:00 p.m.
    ET at the Waldorf Astoria Hotel in New York City
  *Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013
    at 2:30 p.m. ET at the Waldorf Astoria Hotel in New York City
  *RBC Capital Markets Global Healthcare Conference on Tuesday, February 26,
    2013 at 11:30 a.m. ET at the New York Palace Hotel in New York City

Live audio webcasts can be accessed through the Investor Relations page of the
OncoGenex website atwww.oncogenex.com. Webcast replays will be archived for
60 days.

About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com

SOURCE OncoGenex Pharmaceuticals, Inc.

Contact:

Media Contact:
Jaime Welch
jwelch@oncogenex.com
604-630-5403

Investor Relations Contact:
Susan Specht
sspecht@oncogenex.com
425-686-1535